Metabolic activation of 10-aza-substituted benzo[a]pyrene by cytochrome P450 1A2 in human liver microsomes

Kosuge, 1982, Isolation and structural determination of mutagenic substances in coal tar, Chem. Pharm. Bull., 30, 1535, 10.1248/cpb.30.1535 Lacassagne, 1964, Carcinogenic activity of some isosteric nitrogenous pentacyclic hydrocarbon carcinogens, Compt. Rend., 258, 3387 Kitahara, 1978, Synthesis and mutagenicity of 10-azabenzo[a]pyrene-4,5-oxide and other pentacyclic aza-arene oxides, Chem. Pharm. Bull., 26, 1950, 10.1248/cpb.26.1950 Okuda, 1979, Identification of an ultimate mutagen of 10-azabenzo[a]pyrene: microsomal oxidation of 10-azabenzo[a]pyrene to 10-azabenzo[a]pyrene-4,5-oxide, Chem. Pharm. Bull., 27, 2547, 10.1248/cpb.27.2547 Ho, 1981, Analytical and biological analysis of test materials from the synthetic fuel technologies, Mutat. Res., 85, 335, 10.1016/0165-1161(81)90224-7 Yamada, 2002, Effect of 10-aza-substitution on benzo[a]pyrene mutagenicity in vivo and in vitro, Mutat. Res., 521, 187, 10.1016/S1383-5718(02)00240-1 Levin, 1982, Oxidative metabolism of polycyclic aromatic hydrocarbons to ultimate carcinogens, Drug Metab. Rev., 13, 555, 10.3109/03602538209011087 Roberts-Thomson, 1993, The catalytic activity of four expressed human cytochrome P450s towards benzo[a]pyrene and the isomers of its proximate carcinogen, Biochem. Biophys. Res. Commun., 192, 1373, 10.1006/bbrc.1993.1568 Gautier, 1996, Contribution of human cytochrome P450 to benzo[a]pyrene and benzo[a]pyrene-7,8-dihydrodiol metabolism, as predicted from heterologous expression in yeast, Pharmacogenetics, 6, 489, 10.1097/00008571-199612000-00002 Karpukhin, 1974, Synthesis of 3(N)-4-pyridopyrene by the Skraup method, Vestn. Khar’k. Politekh. Inst., 92, 28 Ames, 1975, Methods for detecting carcinogens and mutagens with the Salmonella/mammalian-microsome mutagenicity test, Mutat. Res., 31, 347, 10.1016/0165-1161(75)90046-1 Hakura, 1999, Advantage of the use of human liver S9 in the Ames test, Mutat. Res., 438, 29, 10.1016/S1383-5718(98)00159-4 Hakura, 2001, An improvement of the Ames test using a modified human liver S9 preparation, J. Pharmacol. Toxicol. Meth., 46, 169, 10.1016/S1056-8719(02)00186-7 Hakura, 2003, Use of human liver S9 in the Ames test: assay of three procarcinogens using human S9 derived from multiple donors, Regul. Toxicol. Pharmacol., 37, 20, 10.1016/S0273-2300(02)00024-7 Rodrigues, 1991, Induction of cytochromes P450IA1 and P450IA2 and measurement of catalytic activities, Meth. Enzymol., 206, 423, 10.1016/0076-6879(91)06111-F Fisher, 1992, High-level expression of functional human cytochrome P450 1A2 in Escherichia coli, FASEB J., 6, 759, 10.1096/fasebj.6.2.1537466 Burke, 1994, Cytochrome P450 specificities of alkoxyresorufin O-dealkylation in human and rat liver, Biochem. Pharmacol., 48, 923, 10.1016/0006-2952(94)90363-8 Eugster, 1990, Constitutive and inducible expression of human cytochrome P450IA1 in yeast Saccharomyces cerevisiae: an alternative enzyme source for in vitro studies, Biochem. Biophys. Res. Commun., 172, 737, 10.1016/0006-291X(90)90736-7 Murray, 1993, Human hepatic CYP1A1 and CYP1A2 content, determined with specific anti-peptide antibodies, correlates with the mutagenic activation of PhIP, Carcinogenesis, 14, 585, 10.1093/carcin/14.4.585 Edwards, 1998, Development of a comprehensive panel of antibodies against the major xenobiotic metabolising forms of cytochrome P450 in humans, Biochem. Pharmacol., 56, 377, 10.1016/S0006-2952(98)00033-1 Drahushuk, 1998, Detection of CYP1A1 protein in human liver and induction by TCDD in precision-cut liver slices incubated in dynamic organ culture, Carcinogenesis, 19, 1361, 10.1093/carcin/19.8.1361 Shimada, 1994, Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians, J. Pharmacol. Exp. Ther., 270, 414 Turesky, 1998, Activation of heterocyclic aromatic amines by rat and human liver microsomes and by purified rat and human cytochrome P450 1A2, Chem. Res. Toxicol., 11, 925, 10.1021/tx980022n Saeki, 1997, Modification of the carcinogenic potency of quinoline, a hepatocarcinogen, by fluorine atom substitution: evaluation of carcinogenicity by a medium-term assay, Biol. Pharm. Bull., 20, 40, 10.1248/bpb.20.40 Saeki, 1997, Dual stimulatory and inhibitory effects of fluorine-substitution on mutagenicity: an extension of the enamine epoxide theory for activation of the quinoline nucleus, Biol. Pharm. Bull., 20, 646, 10.1248/bpb.20.646 Kato, 1999, Effects of oligofluorine substitution on the mutagenicity of quinoline: a study with twelve fluoroquinoline derivatives, Mutat. Res., 439, 149, 10.1016/S1383-5718(98)00188-0